Skip to content

Transformative Cancer Therapies.

Targeted Impact.
At Werewolf Therapeutics, we are unleashing the power of proinflammatory immune modulators to develop next-generation, transformative cancer therapeutics. Under precise conditions, our technology allows us to zero in on tumors using validated mechanisms that are known cancer killers, while preventing unwanted side effects on non-target tissues – ultimately delivering a more clinically meaningful impact for patients. Our goal is to vastly improve the lives of a broad range of people living with cancer.
arrow-down

Transforming the Future of Cancer Treatment

We are focused on advancing a novel class of conditionally activated proinflammatory immune modulators. These molecules are designed to act selectively within the tumor microenvironment and recruit a powerful anti-tumor immune response to deliver a clinically meaningful impact for patients.

In contrast to the modulation of immune ‘OFF’ switches such as checkpoint inhibitors, systemic therapy with proinflammatory immune modulators requires exceptional control of delivery, tissue distribution and ultimately, activation to avoid normal tissue inflammation and organ toxicity. In the past, it has been challenging to develop these agents with the appropriate pharmaceutical properties and without off-tissue toxicities.

Our team of experienced scientists embraced this challenge and established a brand-new path forward based on our proprietary platform: PREDATOR™ protein engineering technology. We are designing and engineering the future of immuno-oncology biotherapeutics for patients today.

Predator™ Protein Engineering

Our proprietary PREDATOR™ protein engineering technology allows us to focus on immune targeting and conditional activation in a new way, while enabling novel therapies designed to:
Explore Predator™ Protein Engineering
1
HP-icon-1
HP-icon-1-static
Exhibit superior tolerability and drug-like properties when administered systemically as inactive pro-drugs
2
HP-icon-2
HP-icon-2-static
Undergo transformation to the active state only upon reaching the tumor microenvironment
3
HP-icon-3
HP-icon-3-static
Deliver full biological potency of antitumor immune modulation for maximum therapeutic potential
Explore Predator™ Protein Engineering
split-item-image-initial
split-item-image-alternative

What’s in a name?

The company name is a powerful analogy to our scientific approach. A werewolf is a creature that goes unnoticed in day-to-day life but transforms into a dangerous predator under specific conditions. That is exactly what the medicines that we are developing do.

Our molecules are delivered systemically and remain inactive in the body as they are drawn to the tumor microenvironment, at which point they stimulate a powerful immune response and unleash an attack on cancer cells.

Our proven team

Our team brings together the unmatched determination and dedication of experienced physician-scientists and industry veterans with a proven track record in oncology drug development. Our combined expertise in oncology, immunology, and protein engineering is key for delivering effective cancer immunotherapies to the clinic and market to improve the lives of people who are living with cancer.
Meet our Team
Dan Hicklin, Ph.D.
Founder and Chief Executive Officer
Cynthia Seidel-Dugan, Ph.D.
Chief Scientific Officer
David Cordo
Chief Financial Officer
Reid Leonard, Ph.D.
Chief Operating Officer
Andres Salmeron, Ph.D.
Vice President, Immunology
William Winston, Ph.D.
Vice President, Research
Philipp Steiner, Ph.D.
Vice President, Pharmacology
Anjili Mathur
Senior Director, Portfolio Strategy

Werewolf in the news

Explore the articles, events, and news coverage we’ve received.
Designing conditionally activated immune stimulators that attack cancer cells
As seen in Nature Biopharma Dealmakers Using its proprietary PREDATOR protein engineering platform, Werewolf designs Read More
Pittsburgh Business Times: UPMC Enterprises invests in immunotherapy startup
UPMC Enterprises is part of the investor group for a Massachusetts startup that focuses on immunotherapies, Read More
Smart Business Dealmakers Pittsburgh: UPMC Enterprises Invests In Werewolf Therapeutics
UPMC Enterprises joined a Series A funding round of $56 million for Werewolf Therapeutics. The Cambridge, Massachusetts-based Read More
See all news

Join Us

Are you someone who makes things happen? Do you want to work at a company that embraces the same ideals? We’re looking for vibrant, creative, forward-thinking people to join our team. Click the link below and let us know that you’re interested. We’d love to talk to you.
Protein Biochemist Research Associate/Associate Scientist
Position: Research Associate/Associate Scientist Company Background: Cancer immunotherapy targeting immune checkpoints is demonstrating transformative anti-tumor activity in clinical use, and additional immune regulatory pathways are emerging with the expectation that therapeutics targeting these pathways will rapidly enter
Research Associate, Immunology
WEREWOLF Therapeutics, Inc., Cambridge MA Cancer therapy targeting immune checkpoints has demonstrated transformative anti-tumor activity in clinical use, and additional immune regulatory pathways are emerging with the expectation that therapeutics targeting these pathways will rapidly
Explore opportunities now